CG
NVO

CFO4Life Group’s Novo Nordisk NVO Stock Holding History

CFO4Life Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,957
Closed -$279K – 224
2024
Q2 		$279K Sell
1,957
-739
-27% -$97.9K 0.05% 154
2024
Q1 		$346K Buy
2,696
+425
+19% +$50.6K 0.06% 139
2023
Q4 		$235K Sell
2,271
-86
-4% -$8.51K 0.04% 155
2023
Q3 		$214K Buy
+2,357
New +$208K 0.05% 143

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CFO4Life Group's NVO Position: Q3 2024 in Review

CFO4Life Group sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 1,957 shares — an estimated $279K sold.

CFO4Life Group first reported a position in NVO in Q3 2023 and held it in 4 quarters. The position peaked at $346K in Q1 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • CFO4Life Group reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • CFO4Life Group sold 1,957 Novo Nordisk shares in Q3 2024, an estimated $279K.
  • CFO4Life Group first reported a position in Novo Nordisk in Q3 2023 and held it in 4 quarters.
  • CFO4Life Group's Novo Nordisk position peaked at $346K in Q1 2024.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on CFO4Life Group's 13F filing for Q3 2024, filed 12 Nov 2024.